Anti ar c19

Manufactured by Santa Cruz Biotechnology

Sourced in United States

Anti-AR (C19) is a laboratory reagent used for the detection of androgen receptor (AR) protein in various research applications. It is a polyclonal antibody raised against a synthetic peptide corresponding to the C-terminus of the human AR protein. This antibody can be used in techniques such as Western blotting, immunoprecipitation, and immunohistochemistry to study the expression and localization of AR in biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Ph d 12 peptide library, by New England Biolabs (1 mentions) P3xflag cmv vector, by Merck Group (1 mentions) Lncap, by Merck Group (1 mentions) Lncap, by American Type Culture Collection (1 mentions) Anti ripk1, by Santa Cruz Biotechnology (1 mentions) Anti flag, by Santa Cruz Biotechnology (1 mentions) Anti ezh2, by Abcam (1 mentions) Anti erβ, by GeneTex (1 mentions) Anti setdb1, by Fortis Life Sciences (1 mentions) Anti h3k27me3, by Active Motif (1 mentions) Anti h3k9me2, by Epigentek (1 mentions) Anti h3k9me2, by Active Motif (1 mentions) Anti h3k9me3, by Active Motif (1 mentions) Anti hsp70, by Stressgen (1 mentions) Anti enos, by BD (1 mentions)

3 protocols using anti ar c19

Screening of Prostate Cancer Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

DHT and CDX were obtained from Sigma Chemical Co. (St. Louis, MO) and HF was obtained from Schering-Plough (Kenilworth, NH). The Ph.D.-12 peptide library was purchased from New England Biolabs (Beverly, MA). The human prostate cancer cell lines, PC-3 and LNCaP, were purchased from the American Type Culture Collection (Manassas, VA). The AR expression plasmids PCMV-Flag-AR and pCMX-VP16-AR were constructed as described previously (Nishimura et al., 2003 (link); Yeh and Chang, 1996 (link)). BUD31 cDNA, prepared from human LNCaP cells, was cloned into the p3xFLAG-CMV vector (Sigma Chemical Co.). Motif-mutants of the BUD31 plasmid, p3X-FLAG-mt-AxxAA, were generated by site-directed mutagenesis using a kit obtained from Stratagene (La Jolla, CA). Peptides with the following sequences were synthesized by Genesis Biotech Inc. (Hsintien, Taiwan): Biotin-BUD31p, Biotin-KTRYI-FDLFY-KRKAY; Biotin-3-18, Biotin-NTNA-FSRLF-YPS; Biotin-C320, Biotin-SDSA-FSRLY-TRS; Transactivator of Transcription (TAT), fluorescein-GGGYGRKKRRQRRRG; TAT-BUD31p, fluorescein-TAT-KTRYI-FDLFY-KRKAY; TAT-3-18, fluorescein-TAT-NTNA-FSRLF-YPS; TAT-C320, TAT-SDSA-FSRLY-TRS; and TAT-3-14, fluorescein-TAT-DHSK-LYSLL-QSS. All peptides were dissolved in water. Anti-AR (C19) and anti-BUD31 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and Sigma-Aldrich, respectively.

Hsu C.L., Liu J.S., Wu P.L., Guan H.H., Chen Y.L., Lin A.C., Ting H.J., Pang S.T., Yeh S.D., Ma W.L., Chen C.J., Wu W.G, & Chang C. (2014). Identification of a new androgen receptor (AR) co‐regulator BUD31 and related peptides to suppress wild‐type and mutated AR‐mediated prostate cancer growth via peptide screening and X‐ray structure analysis. Molecular Oncology, 8(8), 1575-1587.

+ Open protocol

+ Expand

Co-immunoprecipitation in 293T Cells

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Details of the co-immunoprecipitation (Co-IP) procedure are described in earlier studies [16 (link), 34 (link)]. 293T cells were employed for our experiments. Anti-Flag, anti-AR (C19), and anti-RIPK1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Hsu C.L., Liu J.S., Lin T.W., Chang Y.H., Kuo Y.C., Lin A.C., Ting H.J., Pang S.T., Lee L.Y., Ma W.L., Lin C.C, & Wu W.G. (2017). Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening. Oncotarget, 8(41), 69508-69519.

+ Open protocol

+ Expand

Comprehensive Antibody Panel for Protein Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used: anti-ERβ (L-20), anti-ERα (HC-20) and anti-AR (C-19) from Santa Cruz Biotechnology, Dallas US-TX; anti-ERβ from GeneTex, Irvine, CA; anti-eNOS from BD Biosciences, Franklin Lakes, US-NJ; anti-phospo-eNOS (Ser1177) from Cell Signaling, Danvers, US-MA; anti-AR (PG-21) from Upstate, Lake Placid, US-NY; anti-ERα Ab-10 (TE111.5D11) from Thermo Fisher Scientific, Fremont, US-CA; anti-KDM1A (also named LSD1), anti-H3K9me3, anti-H3K9me2 and anti-H3K27me3 from Active Motif, Carlsbad, US-CA; anti-H3K9me2 from Epigentek, Farmingdale, US-NY; anti-CBX4 (also named Pc2), anti-KDM1A and anti-SETDB1 from Bethyl Laboratories, Montgomery US-TX; anti-KDM4D (also named JMJD2D) from Novus Biological, Littleton US-CO; anti-EZH2 from Abcam, Cambridge UK; anti-HSP70 from StressGen Biotechnologies, San Diego US-CA.

Aiello A., Bacci L., Re A., Ripoli C., Pierconti F., Pinto F., Masetti R., Grassi C., Gaetano C., Bassi P.F., Pontecorvi A., Nanni S, & Farsetti A. (2016). MALAT1 and HOTAIR Long Non-Coding RNAs Play Opposite Role in Estrogen-Mediated Transcriptional Regulation in Prostate Cancer Cells. Scientific Reports, 6, 38414.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!